+1 more
Depressantmorphine, oxycodone, fentanyl +3 moremorphine, oxycodone, fentanyl, heroin, hydrocodone, methadone show less
Hydromorphone
Hydromorphone (dihydromorphinone) is a semi-synthetic opioid of the morphinan class. It is derived from morphine, distinguished by approximately five times greater oral potency.[1] Hydromorphone is a full agonist at µ-opioid receptors, producing its effects by suppressing pain signaling and depressing respiratory drive.[2]
+1 more
Depressantmorphine, oxycodone, fentanyl +3 moremorphine, oxycodone, fentanyl, heroin, hydrocodone, methadone show less
Synthesized in Germany in 1921, hydromorphone entered clinical practice in 1926 under the brand name Dilaudid as a potent morphine alternative. For most of the twentieth century it remained a second-line painkiller, overshadowed by morphine's entrenched position in hospital formularies. Today it is used in hospitals and pain clinics worldwide, carrying recognition for its safety advantages in patients with kidney impairment.[3]
Subjective effects include profound pain suppression, euphoria, heavy sedation, physical warmth, and the dissolution of anxiety into a deep calm. The experience is defined by what it removes — pain and distress dissolve into a weighted, enveloping quiet, most intensely when delivered intravenously.[4] Nausea, constipation, and mental fog are common; breathing slows, often without the person noticing.
Hydromorphone produces physical dependence quickly, and the gap between a therapeutic dose and a fatal one is dangerously narrow. Tolerance to pain relief builds faster than tolerance to stopped breathing, so escalating the dose steadily narrows the safety margin; adding alcohol or benzodiazepines makes the combination acutely lethal.[5] Six decades of widespread clinical use give hydromorphone one of the strongest pharmacological evidence bases among prescription opioids.
History[edit]
Discovery
Hydromorphone was first synthesized in Germany in 1921 by catalytic hydrogenation of morphine. It was patented in 1923 and brought to market by Knoll pharmaceutical.citation needed Clinical use began in 1926 under the brand name Dilaudid.[6]
Clinical and cultural significance
Within a decade of introduction, over 200 publications had established hydromorphone as a potent analgesic alternative to morphine. It remained a second-line agent for most of the twentieth century, overshadowed by morphine's entrenched formulary position. Its clinical standing improved with the OROS extended-release system (marketed as Jurnista)[7] and recognition that it is safer than morphine for patients with kidney impairment.[3]
Regulation and modern use
Hydromorphone was classified as Schedule II under the United States Controlled Substances Act in 1970, reflecting high abuse potential with accepted medical use.[6] Japan approved it for medical use in 2013.[8] Current research focuses on opioid substitution therapy — where hydromorphone has shown comparable efficacy to diacetylmorphine (heroin) in long-term dependent patients[9] — and abuse-deterrent formulations.[10]
The name Dilaudid was coined to reflect the compound's derivation through laudanum — a nod to its structural kinship with the oldest opiate in continuous human use.[6] Among people who use opioids non-medically, hydromorphone carries a reputation for exceptional intravenous euphoria, earning informal names that reflect both its pharmaceutical origins and its perceived desirability.
Chemistry[edit]
Structural class
Hydromorphone belongs to the morphinan structural family — the same class as morphine, oxymorphone, and codeine. It is produced from morphine by two modifications: converting the C-6 hydroxyl group to a ketone and reducing a double bond. These changes increase its affinity for opioid receptors relative to morphine.[11]
Molecular properties
| Molecular formula | C₁₇H₁₉NO₃ |
| Molecular weight | 285.34 g/mol (free base); 321.80 g/mol (HCl salt) |
The 6-ketone is the key structural difference from morphine and the primary driver of hydromorphone's enhanced potency.[12] Only the active mirror-image form of the molecule is present in pharmaceutical preparations.
Pharmacology[edit]
Mechanism of action
Hydromorphone is a full agonist at mu-opioid receptors — the brain's main pain-control switches — binding with roughly twice the affinity of morphine.[13][2] This suppresses pain signals in the spinal cord and brain and triggers dopamine release in the reward system, producing euphoria. Unlike tramadol or methadone, hydromorphone does not affect serotonin signaling,[14][15] which lowers its risk of serotonin syndrome.
Pharmacokinetics
Oral bioavailability averages around 32%, with wide variation between individuals.[16][17] The liver breaks it down mainly into a metabolite called H3G, which is neuroexcitatory — capable of causing pain hypersensitivity, muscle jerking, and seizures when it builds up.[5] Because hydromorphone lacks the active metabolite that makes morphine problematic in kidney disease, it is often preferred in patients with kidney impairment.[3]
Neuroscience[edit]
Reward and pain circuits
In the brain's reward system, hydromorphone triggers dopamine release in the nucleus accumbens[18] — the mechanism behind euphoria, drug liking, and the compulsive redosing urge. Intravenous delivery reaches the brain quickly, producing an especially intense version of this effect.[4]
In pain pathways, opioid receptor activation in the brain sends inhibitory signals down to the spinal cord, blocking pain before it reaches awareness. Hydromorphone engages these pathways with roughly five times the effectiveness of morphine.[2]
Tolerance and adaptation
With repeated use, opioid receptors become less responsive and the nervous system compensates by strengthening pain-amplifying pathways. H3G, the primary metabolite, accumulates over time[19] and is actively excitatory — capable of causing heightened pain sensitivity, muscle jerking, and seizures,[5] effects that worsen significantly when kidney function is impaired.[20]
- Does hydromorphone's apparent preference for one signaling pathway over another[8] translate to measurably fewer adverse effects at clinical doses?
- At what blood concentration does H3G become clinically symptomatic — and how much does this threshold vary between individuals?
- No neuroimaging studies have compared the long-term brain effects of hydromorphone versus morphine, leaving open whether their different metabolite profiles produce divergent patterns of neural adaptation.
Subjective Effects[edit]
Hydromorphone produces a rapid convergence of pain suppression, warmth, and calm. Distress and discomfort dissolve together, leaving a heavy, enveloping quiet — more like switching something off than adding something new. The experience is dominated by its sedative and analgesic character rather than mood elevation or mental stimulation.
Relative to morphine, hydromorphone delivers a comparable experience at one-fifth the oral dose, with marginally less nausea. Compared to oxycodone, the reinforcing profile at equivalent doses is similar[18] — making potency a poor guide to predicting which drug a person will find more compelling.
Synthesized in Germany in 1921 through catalytic hydrogenation of morphine, hydromorphone entered clinical practice in 1926 under the brand name Dilaudid. It served as a second-line analgesic behind morphine for most of the twentieth century before gaining recognition for its favorable metabolic profile in patients with kidney impairment.[3] It remains a Schedule II controlled substance in the United States and is listed under the strictest medicinal narcotic schedules in most major jurisdictions.
Subjective effects include profound analgesia, euphoria, sedation, anxiolysis, and physical warmth. The experience is one of rapid, enveloping somatic relief — pain and distress dissolve into a heavy calm that narrows attention to a quiet, weighted drift, particularly intense when delivered intravenously.[4] Nausea, constipation, cognitive impairment, and respiratory slowing are characteristic unsought effects.
Hydromorphone produces rapid physical dependence and carries a narrow therapeutic index — respiratory depression is the primary mechanism of fatal overdose. Tolerance to analgesia develops faster than tolerance to respiratory depression, so dose escalation progressively narrows the safety margin; the neuroexcitatory metabolite H3G accumulates to dangerous levels in kidney impairment.[5] Six decades of clinical use and extensive pharmacological characterization provide a robust evidence base for hydromorphone's risk profile.
History[edit]
Discovery
Hydromorphone was first synthesized in Germany in 1921 through catalytic hydrogenation of morphine — a reaction that converts the C-6 hydroxyl group to a ketone and reduces the C7–C8 double bond. The compound was patented in 1923 and brought to market by the Knoll pharmaceutical company.citation needed Clinical introduction followed in 1926 under the brand name Dilaudid.[6]
Clinical and cultural significance
Within a decade of introduction, over 200 publications had documented hydromorphone's analgesic properties, establishing it as a potent alternative to morphine. Despite this early recognition, hydromorphone remained a second-line agent for most of the twentieth century — overshadowed by morphine's entrenched formulary position and the absence of extended-release formulations. Its clinical standing shifted with the development of the OROS once-daily delivery system (marketed as Jurnista)[7] and recognition of its safety advantage over morphine in patients with kidney impairment.[3]
Regulation and modern use
Hydromorphone was classified as a Schedule II substance under the United States Controlled Substances Act of 1970, reflecting high abuse potential with accepted medical use.[6] Japan approved it for medical use in 2013.[8] Contemporary research centers on opioid substitution therapy — where hydromorphone has demonstrated comparable efficacy to diacetylmorphine (heroin) in long-term dependent patients[9] — and abuse-deterrent formulations incorporating naloxone.[10]
The name Dilaudid was coined to reflect the compound's derivation from morphine through laudanum — a deliberate nod to its structural kinship with the oldest opiate in continuous human use.[6] Among people who use opioids non-medically, hydromorphone carries a reputation for exceptional intravenous euphoria, earning informal names that reflect both its pharmaceutical origins and its perceived desirability relative to other prescription opioids.
Chemistry[edit]
Structural class
Hydromorphone belongs to the morphinan structural class — the phenanthrene-type opioids sharing the 4,5-epoxymorphinan skeleton with morphine, oxymorphone, and codeine. It is produced from morphine by two modifications at the C-ring: oxidation of the C-6 hydroxyl to a ketone and reduction of the C7–C8 double bond. These changes increase lipophilicity and enhance μ-opioid affinity relative to morphine.[11]
Molecular properties
| Molecular formula | C₁₇H₁₉NO₃ |
| Molecular weight | 285.34 g/mol (free base); 321.80 g/mol (HCl salt) |
The morphinan skeleton comprises a pentacyclic ring system: a benzene ring (A), two partially saturated cyclohexane rings (B, C), a piperidine ring (D), and a tetrahydrofuran ring (E, formed by the 4,5-epoxy bridge). The N-methyl group at position 17 is characteristic of the morphinan series. The 6-ketone — the key structural difference from morphine's 6-hydroxyl — is the primary determinant of hydromorphone's enhanced potency.[12]
Stereochemistry
Hydromorphone contains multiple chirality centers. Only the levorotatory enantiomer (5α configuration) produces opioid agonist activity; all pharmaceutical preparations contain exclusively this active form. The dextrorotatory enantiomer has not been pharmacologically characterized in humans.
Physical properties
Hydromorphone hydrochloride is a fine, white, odorless crystalline powder. It is freely soluble in water, slightly soluble in ethanol, and practically insoluble in nonpolar organic solvents.citation needed
Pharmacology[edit]
Mechanism of action
Hydromorphone is a selective full agonist at the μ-opioid (MOR), binding with very high affinity — roughly twice that of morphine.[13][2] Activation of MOR triggers a signaling cascade that inhibits pain transmission at both spinal and brain levels: cellular excitability drops, pain signals are suppressed, and downstream dopamine release drives the compound's euphoric and reinforcing properties.
Comprehensive receptor screening has found no significant activity at kappa, delta, or nociceptin opioid receptors, nor at monoamine transporters.[14] Hydromorphone does not block serotonin or norepinephrine reuptake,[15][16] distinguishing it from opioids like tramadol and methadone that carry serotonin syndrome risk.
Laboratory studies suggest hydromorphone may preferentially activate the G-protein signaling pathway over the beta-arrestin pathway — a pattern hypothesized to produce analgesia with potentially fewer side effects.[8] Whether this translates to clinical benefit remains unconfirmed.
Pharmacokinetics
Oral bioavailability averages approximately 32%, with wide individual variation (17–62%), due to extensive first-pass metabolism in the liver.[17][18] Immediate-release formulations reach peak blood levels within 30–60 minutes, with analgesic onset at 15–30 minutes.[19] The OROS extended-release formulation peaks at approximately 5 hours and delivers sustained levels over 24 hours.[20]
Intranasal administration roughly doubles oral bioavailability (52–58%) with faster onset.[21] Intravenous delivery provides complete bioavailability with near-immediate effect.
The body breaks down hydromorphone primarily through glucuronidation in the liver, producing hydromorphone-3-glucuronide (H3G) as the dominant metabolite. H3G accumulates at a 27:1 ratio relative to the parent drug at steady state[20] and is neuroexcitatory — capable of producing pain hypersensitivity, muscle jerking, and seizures.[5] Crucially, hydromorphone does not produce an active 6-glucuronide metabolite, which is why it is often preferred over morphine in patients with kidney impairment.[3]
The half-life is 2–3 hours for immediate-release formulations[18] and approximately 11 hours for the extended-release system.[7] Plasma protein binding is low (8–19%),[3] and excretion is primarily renal.
Neuroscience[edit]
Reward and pain circuits
Hydromorphone's central effects operate through two principal neural systems. In the mesolimbic reward pathway, μ-opioid activation in the ventral tegmental area releases dopamine into the nucleus accumbens — the mechanism underlying euphoria, drug liking, and compulsive redosing urge.[22] The pronounced euphoria of intravenous delivery[4] reflects rapid central arrival enabling efficient activation of this circuit.
In descending pain pathways, mu-opioid receptor activation in the periaqueductal gray triggers inhibitory signals that travel down to the spinal cord, suppressing incoming pain messages before they reach conscious awareness. Hydromorphone's analgesic potency — five times morphine orally — reflects its higher receptor affinity and efficient engagement of these circuits.[2]
Tolerance and adaptation
Repeated mu-opioid receptor activation leads to receptor desensitization and internalization, reducing the brain's response to the same dose over time. Chronic exposure also triggers compensatory changes: the cellular signaling pathways that opioids suppress rebound effect into a hyperactive state, and excitatory glutamate systems strengthen. These adaptations underlie both analgesic tolerance and physical dependence.
An additional dimension unique to hydromorphone is its neuroexcitatory metabolite H3G, which accumulates at a 27:1 ratio.[20] H3G can produce pain hypersensitivity, muscle jerking, and seizures[5] — effects that overlay the inhibitory opioid state and become clinically significant in kidney impairment.[23]
- Does hydromorphone's apparent G-protein signaling bias[8] translate to measurably reduced side effects at clinical doses?
- At what blood concentration does H3G become clinically symptomatic in humans — and how does this threshold vary between individuals?
- No neuroimaging studies have compared the long-term brain effects of hydromorphone versus morphine, leaving open whether their different metabolite profiles produce divergent patterns of neural adaptation over months to years.
Subjective Effects[edit]
The hydromorphone experience centers on a rapid convergence of pain suppression, physical warmth, and the dissolution of anxiety into a state of heavy, enveloping calm. Route of administration shapes the character more than with most opioids: oral dosing builds gradually into sustained sedation, while intravenous delivery produces an immediate euphoric surge disproportionately intense relative to the oral experience. Tolerance status fundamentally alters the qualitative profile — opioid-naive individuals encounter the full euphoric and sedative sweep at doses that produce only analgesia in tolerant users.
Relative to morphine, hydromorphone delivers comparable subjective quality at one-fifth the oral dose, with marginally less nausea and constipation but equivalent respiratory depression risk. Compared to oxycodone and hydrocodone, oral hydromorphone produces similar reinforcement despite its greater analgesic potency[22] — a dissociation that makes potency a poor predictor of abuse potential.
Effect Grid
Full analgesic effect with clear euphoria and enveloping physical warmth. Anxiety suppression is pronounced — worries recede as a pervasive sense of contentment settles in. Cognitive euphoria is unmistakable: a warm, satisfied mental state accompanied by thought deceleration and mild cognitive impairment. Emotional suppression flattens both positive and negative affect into comfortable neutrality.
Moderate sedation makes sustained attention difficult. Pupil constriction is prominent. Nausea and constipation are common. Respiratory depression is measurable but rarely clinically dangerous in isolation for opioid-naive individuals without co-intoxicants. Body high and tactile euphoria are characteristic — physical contact and soft textures feel enhanced.
Functional impairment is significant. Driving and operating machinery are unsafe. Duration is 3–5 hours orally; aftereffects may persist for hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sedation · Bodily heaviness · Body high · Breathing alteration · Tactile euphoria · Sexual arousal suppression · Nausea · Spontaneous body sensations · Muscle relaxation · Physical fatigue · Appetite suppression · Dizziness · Excessive sweating · Dry mouth · Temperature dysregulation · Tingling / electric sensations · Vomiting · Abnormal heartbeat · Heart rate perception changes · Vibrations / buzzing · Involuntary body movements
Breathing alteration · Tactile euphoria · Sexual arousal suppression · Nausea · Spontaneous body sensations · Muscle relaxation · Physical fatigue · Appetite suppression · Dizziness · Excessive sweating · Dry mouth · Tingling / electric sensations · Vomiting · Abnormal heartbeat · Heart rate perception changes · Vibrations / buzzing · Involuntary body movements
Focus suppression · Information processing suppression · Thought deceleration · Analysis suppression · Motivation suppression · Confusion · Language suppression · Memory suppression · Cognitive dysphoria · Delusions of sobriety · Thought disorganization
Analysis suppression · Motivation suppression · Confusion · Language suppression · Memory suppression · Cognitive dysphoria · Thought disorganization
Dysphoria
Disinhibition · Depersonalization · Derealization · Cognitive disconnection
Timeline
Subtle warmth begins spreading through the body. Initial awareness of an altered state — a quiet shift in baseline mood and faint softening of discomfort.
Analgesia and physical warmth build steadily. Anxiolysis develops as mental chatter quiets. Mild pupil constriction and early nausea may appear in opioid-naive users.
Full analgesic and euphoric effect. Maximum sedation and enveloping warmth. Cognitive effects maximal — thought deceleration, emotional flattening, and contented detachment.
Gradual diminution of euphoria and analgesia. Residual sedation and warmth persist. Pain may begin to re-emerge.
Mild residual sedation and warmth. Constipation may linger. Mood may be slightly flat as opioid effects recede.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · oxycodone · fentanyl
Toxicity
Acute toxicity
No human lethal dose has been established. The margin between a therapeutic dose and a fatal one depends entirely on tolerance — amounts that are safe in tolerant individuals can kill an opioid-naive person.
Overdose presents as progressive sedation, respiratory depression (breathing slowing below 12 breaths per minute, eventually stopping), pinpoint pupils, blue lips and skin, low blood pressure, and slow heart rate.[21]
Naloxone (0.4–2 mg intravenously, intramuscularly, or subcutaneously) reverses hydromorphone overdose. Repeat doses every 2–3 minutes may be needed (maximum approximately 10 mg total). Naloxone wears off in 30–90 minutes while hydromorphone's effects last 2–3 hours — breathing can slow again after initial reversal. Sustained monitoring and assisted breathing are required until the person demonstrates independent respiration.[21]
Metabolite toxicity
The primary metabolite H3G accumulates at a 27:1 ratio at steady state[19] and is neuroexcitatory — causing heightened pain sensitivity, involuntary muscle jerking, and seizures.[5] In kidney impairment, H3G concentrations reach approximately four times normal levels.[20] Switching to an opioid without neuroexcitatory metabolites (such as methadone or fentanyl) typically resolves these symptoms.[5]
Organ-specific toxicity
Respiratory: respiratory depression is the primary cause of opioid overdose death. Alcohol, benzodiazepines, and other CNS depressants worsen it in a dose-dependent way.
Gastrointestinal: constipation is nearly universal with chronic use. Hydromorphone may produce marginally fewer gastrointestinal effects than morphine.[22]
Endocrine: Chronic opioid use suppresses sex hormone production, leading to sexual dysfunction, infertility, depression, and bone loss. This is a class effect across all μ-opioid agonists.citation needed
Liver: Severe liver impairment increases oral bioavailability and slows clearance, requiring dose reduction.[16]
Kidneys: H3G accumulates in kidney failure. Despite this, hydromorphone is often preferred over morphine in this population because it lacks morphine's active 6-glucuronide metabolite.[3][23] Dose reduction and monitoring for neuroexcitatory symptoms are required.
Psychological risks
Hydromorphone carries high addiction potential, reflected in its Schedule II classification.[6] In opioid-naive individuals, a single euphorigenic dose can initiate craving and compulsive drug-seeking.[4] Intravenous use carries particularly high addiction liability due to rapid onset and intense euphoria.[10]
Oral hydromorphone's reinforcing profile is comparable to oral oxycodone and hydrocodone,[18] despite its greater analgesic potency. Long-term non-therapeutic use carries risks of chronic depression, inability to experience pleasure, and social deterioration.
Tolerance and dependence
Tolerance to analgesia and euphoria develops within days to weeks of regular use. Constipation tolerance builds slowly or not at all. Cross-tolerance with other mu-opioid agonists (Morphine, oxycodone, Fentanyl, heroin) is well established but incomplete — standard practice applies a 25–50% dose reduction at the equianalgesic ratio.[24]
Physical dependence develops over days to weeks. Stopping abruptly brings withdrawal: anxiety, restlessness, sweating, rapid heart rate, dilated pupils, muscle aches, stomach cramping, diarrhea, and insomnia. Onset is typically 4–12 hours after the last dose; the acute phase lasts 5–10 days; prolonged symptoms can persist for weeks to months.citation needed
Hydromorphone has been evaluated in opioid substitution treatment, showing comparable efficacy to diacetylmorphine (heroin) in long-term dependent patients.[9]
Drug Interactions
The main interaction risk is potentiation of breathing suppression when combined with other depressants. Drug metabolism interactions are minimal because hydromorphone is cleared by glucuronidation rather than the cytochrome P450 enzyme system.
Central nervous system depressant synergy
Alcohol: Additive breathing suppression and sedation. Deaths occur at relatively modest combined doses. The OROS extended-release formulation does not release its full dose when taken with alcohol,[3] but the pharmacological danger of the combination remains.
Benzodiazepines: Synergistic respiratory depression — a major contributor to opioid overdose deaths.safety citation needed
GHB/GBL: Dramatically potentiate opioid-induced respiratory depression. The combination carries lethal risk.
Other opioids: Additive respiratory depression; concurrent use requires careful dose adjustment under medical supervision.
Serotonin-related interactions
Hydromorphone does not block serotonin reuptake,[14][15] distinguishing it from tramadol, meperidine, tapentadol, and methadone. The risk of serotonin syndrome from hydromorphone is low.
MAO inhibitors
Co-administration with monoamine oxidase inhibitors is contraindicated — the combination risks severe CNS depression and potentially fatal reactions. A minimum 14-day washout period is required after stopping an MAOI.safety citation needed
Metabolic interactions
Rifampin modestly reduces hydromorphone blood levels,[25] but the clinical impact is limited because glucuronidation handles most clearance.
Contraindications
10 knownAbsolute contraindications:
- Severe breathing impairment — severe asthma in unmonitored settings, severe chronic lung disease with CO₂ retention. Opioid-induced respiratory depression compounds existing difficulty.
- Bowel obstruction or paralytic ileus. Opioids slow gut movement further, risking perforation.
- MAO inhibitor use within 14 days.
- Known allergy to hydromorphone or sulfite excipients in some formulations.
Relative contraindications:
- Kidney impairment — requires dose reduction and monitoring for H3G-mediated neuroexcitatory effects.[23]
- Liver impairment — increased bioavailability and decreased clearance require dose reduction.[16]
- Pregnancy — risk of neonatal opioid withdrawal and breathing depression in the newborn.safety citation needed
- Concurrent CNS depressant use — preferably avoided outside supervised clinical settings.
- Elderly patients — increased sensitivity to respiratory and sedative effects; dose reduction recommended.[26]
Harm Reduction[edit]
Forms & Identification
Pharmaceutical hydromorphone comes as scored tablets, oral liquid, injectable ampoules, and rectal suppositories — all with manufacturer markings and standardized concentrations. Diverted pharmaceutical tablets are generally what they appear to be, but imprints should be cross-referenced against published identification databases.
Any tablet obtained outside a pharmacy should be treated as unverified regardless of appearance. Counterfeits may contain fentanyl or fentanyl analogs at unpredictable concentrations — appearance alone cannot confirm identity.
Guidelines
- Test any tablet of uncertain origin with fentanyl test strips before use.
- Start with the lowest effective dose, particularly if tolerance has changed — even a few days of abstinence significantly reduces tolerance.
- Oral administration carries the lowest acute risk due to slower onset and lower peak blood levels. Avoid intravenous use where possible — it maximizes both overdose risk and abuse liability.
- If injecting, use sterile equipment, rotate injection sites, and never inject crushed extended-release tablets — the matrix material causes vein damage and embolic injury.
- Do not combine with alcohol, benzodiazepines, GHB, or other depressants. This is the most common cause of opioid overdose death.
- Have naloxone immediately accessible. Multiple doses may be needed because naloxone wears off faster than hydromorphone.
- Eat before use — nausea is more likely on an empty stomach.
- Do not redose within 4 hours of an oral dose. The compulsive redosing urge before full onset is a common precursor to accidental overdose.
Set & Setting
Hydromorphone is a powerful CNS depressant. Using alone — particularly by injection — means no one is present to intervene if breathing stops. A trusted, sober companion who can recognize overdose and administer naloxone meaningfully reduces the risk of a fatal outcome.
A calm, familiar environment reduces anxiety-driven dose escalation. Avoid any situation requiring alertness, coordination, or physical safety — driving, swimming, heights, or machinery.
Aftercare & integration. Constipation is cumulative and does not resolve spontaneously — maintain hydration and fiber intake. Nausea typically diminishes with repeated doses but may benefit from ginger or antiemetic medication during early use.
For pain management use, track the relationship between dose and pain suppression over time. Dose escalation that outpaces clinical need is an early warning sign of developing dependence. For non-medical use, the shift from occasional to daily use often happens gradually and without a clear decision point.
Recovery & Support
Physical dependence on hydromorphone develops within days to weeks of regular use. Withdrawal is intensely uncomfortable but not typically life-threatening in otherwise healthy individuals. Medical support significantly reduces suffering and improves completion rates.
Medically supervised options:
- Buprenorphine (Suboxone): Partial μ-opioid agonist that suppresses withdrawal and cravings. Initiation requires waiting until moderate withdrawal symptoms appear to avoid precipitated withdrawal.
- Methadone: full agonist substitution therapy available through licensed clinics. Effective for long-term stabilization.
- Supervised tapering: Gradual dose reduction under medical guidance.
Support resources:
- SAMHSA National Helpline: 1-800-662-4357 (US, free, confidential, 24/7)
- Never Use Alone hotline: 1-800-484-3731 (US — stay on the line while using so help can be called if breathing stops)
- Local harm reduction organizations often provide naloxone, sterile supplies, and referrals to treatment.
Relapse is common and does not represent failure — it represents a point of elevated overdose risk because tolerance has decreased during abstinence.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing is slow (fewer than 12 breaths per minute), shallow, or has stopped
- Lips, fingertips, or skin are turning blue or gray
- Person is unresponsive — does not react to shouting, sternal rub, or pain
- Gurgling, choking, or snoring sounds while unconscious
Immediate steps:
- 1. Call emergency services immediately.
- 2. Administer naloxone if available — 0.4–2 mg intranasally or intramuscularly. If no response in 2–3 minutes, give a second dose.
- 3. Place the person in the recovery position (on their side) to prevent choking on vomit.
- 4. If not breathing, begin rescue breathing or CPR.
- 5. Stay with the person. Naloxone wears off in 30–90 minutes — breathing may stop again.
- 6. Do NOT leave the person alone after naloxone administration, even if they appear to recover.
What to tell the dispatcher: Substance taken (hydromorphone/opioid), approximate amount, time of last dose, current symptoms (not breathing, unconscious, blue lips). Good Samaritan laws in many jurisdictions protect people who call for help during an overdose — calling can save a life without legal consequence.
Reversal agent: Naloxone reverses opioid overdose. It is available without prescription in many jurisdictions as a nasal spray (Narcan) or injectable kit. Keep it wherever hydromorphone is used or stored.
Legal Status[edit]
Hydromorphone is internationally controlled as a narcotic with accepted medical use, listed under Schedule I of the 1961 United Nations Single Convention on Narcotic Drugs.citation needed Most major jurisdictions require special prescription forms, triplicate records, or electronic reporting.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act, 1970) | High abuse potential with accepted medical use; no refills; prescriber DEA registration required[6] |
| United Kingdom | Class A (Misuse of Drugs Act 1971); Schedule 2 (MDR 2001) | Maximum penalties for unlawful supply; available on prescription with controlled drug requirementscitation needed |
| Canada | Schedule I (Controlled Drugs and Substances Act) | Available as Hydromorph Contin and Dilaudid; controlled drug prescribing regulations applycitation needed |
| Australia | Schedule 8 (Controlled Drug — Poisons Standard) | TGA regulated; state and territory prescription requirementscitation needed |
| Germany | Anlage III (Betäubungsmittelgesetz / BtMG) | Most restrictive medicinal narcotic schedule; special prescription form (BtM-Rezept) requiredcitation needed |
| Japan | Narcotic (Narcotics and Psychotropics Control Act) | Approved for medical use in 2013[8] |
| European Union | Controlled narcotic (member-state schedules vary) | Regulated under 1971 UN Convention framework; individual member states set prescription requirements |
Legal status varies by jurisdiction and changes over time. This information is not legal advice — verify current local regulations before drawing any legal conclusions.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · oxycodone · fentanyl
Toxicity
Acute toxicity
No human lethal dose has been established for hydromorphone. The therapeutic index is narrow, and the margin between an effective dose and a fatal dose depends critically on tolerance status — amounts that are therapeutic in tolerant individuals can kill opioid-naive users.
Overdose presents as progressive sedation leading to unconsciousness, respiratory depression (breathing rate below 12 breaths per minute, progressing to breathing cessation), pinpoint pupils (which may be absent in mixed overdoses), blue discoloration of lips and skin, low blood pressure, and slow heart rate.[19]
Naloxone (0.4–2 mg intravenously, intramuscularly, or subcutaneously) reverses hydromorphone overdose. Repeat doses every 2–3 minutes may be needed (maximum approximately 10 mg total). Because hydromorphone outlasts naloxone — the opioid's half-life is 2–3 hours while naloxone wears off in 30–90 minutes — breathing can slow again after initial reversal. Assisted breathing must be maintained until the person demonstrates sustained spontaneous respiration.[19]
Metabolite toxicity
The primary metabolite hydromorphone-3-glucuronide (H3G) accumulates at a 27:1 ratio at steady state[20] and is neuroexcitatory — capable of producing heightened pain sensitivity, involuntary muscle jerking, and seizures.[5] In patients with kidney impairment, H3G concentrations rise to approximately four times normal levels.[23] Switching to an opioid that does not produce neuroexcitatory metabolites (such as methadone or fentanyl) typically resolves these symptoms.[5]
Organ-specific toxicity
Respiratory: respiratory depression is the primary cause of opioid overdose death. The effect is dose-dependent and synergistically worsened by alcohol, benzodiazepines, and other central nervous system depressants.
Gastrointestinal: constipation is nearly universal with chronic use. Hydromorphone may produce marginally fewer gastrointestinal side effects than morphine.[24]
Endocrine: Chronic opioid use suppresses sex hormone production (opioid-induced hypogonadism), leading to sexual dysfunction, infertility, depression, and decreased bone density. This is a class effect shared by all μ-opioid agonists.citation needed
Liver: In severe liver impairment, reduced first-pass metabolism increases oral bioavailability and slows clearance, requiring dose reduction.[17]
Kidneys: H3G accumulation is the primary safety concern in kidney failure. Hydromorphone is nonetheless often preferred over morphine in this population because it lacks the active morphine-6-glucuronide metabolite.[3][25] Dose reduction and monitoring for neuroexcitatory symptoms are required.
Psychological risks
Hydromorphone carries high addiction potential, reflected in its Schedule II classification.[6] In opioid-naive individuals, a single euphorigenic dose can initiate craving and compulsive drug-seeking.[4] Intravenous use carries particularly high abuse liability due to rapid delivery and pronounced euphoria.[10]
The reinforcing profile of oral hydromorphone is comparable to oral oxycodone and hydrocodone,[22] despite hydromorphone's greater analgesic potency. This dissociation means analgesic potency is a poor predictor of addiction risk.
Long-term non-therapeutic use carries risks of chronic depression, inability to experience pleasure, social isolation, and occupational deterioration — consequences of sustained disruption to the brain's reward circuitry. No controlled studies have specifically characterized these effects for hydromorphone.
Tolerance and dependence
Tolerance to hydromorphone's analgesic and euphoric effects develops within days to weeks of regular dosing. Constipation tolerance develops slowly if at all — a clinically important asymmetry.
Cross-tolerance with other mu-opioid agonists (Morphine, oxycodone, Fentanyl, heroin) is well established but incomplete. Standard opioid rotation practice applies a 25–50% dose reduction at the equianalgesic ratio to account for incomplete cross-tolerance.[26]
Physical dependence develops with regular use over days to weeks. Abrupt discontinuation produces withdrawal: anxiety, restlessness, sweating, rapid heart rate, dilated pupils, muscle aches, stomach cramping, diarrhea, and insomnia. Onset is typically 4–12 hours after the last dose, peak severity at 36–72 hours, acute phase duration 5–10 days. Prolonged withdrawal symptoms — inability to experience pleasure, insomnia, low mood — can persist for weeks to months.citation needed
Hydromorphone has been evaluated in opioid substitution treatment programs, where conversion studies have compared it to diacetylmorphine (heroin) for long-term dependent patients.[9]
Drug Interactions
The interaction profile is dominated by pharmacodynamic potentiation of respiratory and central nervous system depression with co-administered depressants. Drug metabolism interactions are minimal because hydromorphone is cleared primarily through glucuronidation, not the cytochrome P450 enzyme system.
Central nervous system depressant synergy
Alcohol: Additive respiratory and central nervous system depression. Deaths occur at relatively modest combined doses. The OROS extended-release formulation does not release its full dose when taken with alcohol (unlike some extended-release morphine formulations),[3] but the pharmacological danger of the combination remains.
Benzodiazepines: Synergistic respiratory depression responsible for a significant proportion of opioid overdose deaths.safety citation needed
GHB/GBL: Dramatically potentiate opioid-induced respiratory depression. The combination carries lethal risk.
Other opioids: Additive respiratory depression; concurrent use requires careful dose adjustment under medical supervision.
Serotonin-related interactions
Hydromorphone does not block serotonin reuptake,[15][16] distinguishing it from tramadol, meperidine, tapentadol, and methadone. The risk of serotonin syndrome from hydromorphone alone or in combination with serotonergic medications is low.
MAO inhibitors
Co-administration with monoamine oxidase inhibitors is contraindicated — risk of severe central nervous system depression and potentially fatal reactions. A minimum 14-day washout period is required between stopping an MAOI and starting hydromorphone.safety citation needed
Metabolic interactions
Rifampin modestly reduces hydromorphone blood levels,[27] but the clinical impact is limited because glucuronidation — not cytochrome P450 metabolism — is the primary clearance route.
Contraindications
10 knownAbsolute contraindications:
- Significant breathing impairment — severe asthma in unmonitored settings, severe chronic lung disease with carbon dioxide retention. Opioid-induced respiratory depression compounds existing breathing difficulty.
- Bowel obstruction or paralytic ileus. Opioids further slow gut motility, risking perforation in the setting of obstruction.
- MAO inhibitor use within 14 days.
- Known allergy to hydromorphone or sulfite excipients present in some formulations.
Relative contraindications:
- Kidney impairment — requires dose reduction and monitoring for H3G-mediated neuroexcitatory effects.[25]
- Liver impairment — increased bioavailability and decreased clearance require dose reduction.[17]
- Pregnancy — risk of neonatal opioid withdrawal syndrome and breathing depression in the newborn.safety citation needed
- Concurrent central nervous system depressant use — preferably avoided outside supervised clinical settings.
- Elderly patients — increased sensitivity to respiratory and sedative effects; dose reduction recommended.[28]
Harm Reduction[edit]
Forms & Identification
Pharmaceutical hydromorphone circulates as scored tablets, oral liquid, injectable ampoules, and rectal suppositories — all bearing manufacturer markings, lot numbers, and standardized concentrations. Diverted pharmaceutical product is generally what it claims to be, but verification matters: tablet imprints can be cross-referenced against published identification databases.
The critical identification concern is distinguishing genuine pharmaceutical product from counterfeit tablets, which may contain fentanyl or fentanyl analogs at unpredictable concentrations. Any tablet obtained outside a pharmacy should be treated as unverified regardless of appearance.
Guidelines
- Test any tablet of uncertain origin with fentanyl test strips before use.
- Start with the lowest effective dose, particularly if tolerance status is uncertain or has changed — even a few days of abstinence significantly reduces tolerance.
- Oral administration carries the lowest acute risk profile due to slower onset and lower peak blood levels. Avoid intravenous use where possible — it maximizes both overdose risk and abuse liability.
- If injecting, use sterile equipment, rotate injection sites, and never inject crushed extended-release tablets — the matrix material can cause vein damage and embolic injury.
- Do not combine with alcohol, benzodiazepines, GHB, or other depressants. This is the most common cause of opioid overdose death.
- Have naloxone immediately accessible. Multiple doses may be needed because naloxone wears off faster than hydromorphone.
- Eat before use — nausea is more likely on an empty stomach.
- Do not redose within 4 hours of an oral dose. The compulsive redosing urge before full onset is a common precursor to accidental overdose.
Set & Setting
Hydromorphone is a powerful central nervous system depressant. Using alone — particularly via injection — means no one is present to intervene if breathing stops. A trusted, sober companion who can recognize overdose signs and administer naloxone meaningfully reduces the risk of fatal outcome.
A calm, familiar environment reduces anxiety-driven dose escalation. Avoid situations requiring alertness, coordination, or physical safety — driving, swimming, heights, or operating machinery.
Aftercare & integration. The period following opioid use requires attention to physical recovery. Constipation is cumulative and does not resolve spontaneously — maintain hydration and fiber intake. Nausea typically diminishes with repeated doses but may benefit from ginger or antiemetic medication during early use.
If using hydromorphone for pain management, track the relationship between dose and pain suppression over time. Dose escalation that outpaces clinical need is an early warning sign of developing dependence. For individuals using non-medically, honest self-assessment of use frequency and dose trajectory matters — the transition from occasional to daily use often happens gradually and without a clear decision point.
Recovery & Support
Physical dependence on hydromorphone develops within days to weeks of regular use. Withdrawal is intensely uncomfortable but not typically life-threatening in otherwise healthy individuals. Medical support significantly reduces suffering and improves completion rates.
Medically supervised options:
- Buprenorphine (Suboxone): Partial μ-opioid agonist that suppresses withdrawal and cravings. Initiation requires waiting until moderate withdrawal symptoms appear to avoid precipitated withdrawal.
- Methadone: full agonist substitution therapy available through licensed clinics. Effective for long-term stabilization.
- Supervised tapering: Gradual dose reduction under medical guidance.
Support resources:
- SAMHSA National Helpline: 1-800-662-4357 (US, free, confidential, 24/7)
- Never Use Alone hotline: 1-800-484-3731 (US — stay on the line while using so someone can call help if you stop responding)
- Local harm reduction organizations often provide naloxone, sterile supplies, and referrals to treatment.
Recovery is not a single event. Relapse is common and does not represent failure — it represents a point of elevated overdose risk because tolerance has decreased during abstinence.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing is slow (fewer than 12 breaths per minute), shallow, or has stopped
- Lips, fingertips, or skin are turning blue or gray
- Person is unresponsive — does not react to shouting, sternal rub, or pain
- Gurgling, choking, or snoring sounds while unconscious
Immediate steps:
- 1. Call emergency services immediately.
- 2. Administer naloxone if available — 0.4–2 mg intranasally or intramuscularly. If no response in 2–3 minutes, give a second dose.
- 3. Place the person in the recovery position (on their side) to prevent choking on vomit.
- 4. If not breathing, begin rescue breathing or CPR.
- 5. Stay with the person. Naloxone wears off in 30–90 minutes — breathing may stop again.
- 6. Do NOT leave the person alone after naloxone administration, even if they appear to recover.
What to tell the dispatcher: Substance taken (hydromorphone/opioid), approximate amount, time of last dose, current symptoms (not breathing, unconscious, blue lips). Good Samaritan laws in many jurisdictions protect people who call for help during an overdose — calling can save a life without legal consequence.
Reversal agent: Naloxone reverses opioid overdose. It is available without prescription in many jurisdictions as a nasal spray (Narcan) or injectable kit. Keep it wherever hydromorphone is used or stored.
Legal Status[edit]
Hydromorphone is internationally controlled as a narcotic substance with accepted medical use. It is listed under Schedule I of the 1961 United Nations Single Convention on Narcotic Drugs, requiring all signatory states to limit manufacture, trade, distribution, and use to medical and scientific purposes.citation needed
In most major jurisdictions, hydromorphone occupies the most restrictive schedule for medically useful controlled substances. Prescription requirements are stringent: no refills are permitted for Schedule II substances in the US, and most jurisdictions require special prescription forms, triplicate records, or electronic reporting.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act, 1970) | High abuse potential with accepted medical use; no refills; prescriber DEA registration required[6] |
| United Kingdom | Class A (Misuse of Drugs Act 1971); Schedule 2 (MDR 2001) | Maximum penalties for unlawful supply; available on prescription with controlled drug requirementscitation needed |
| Canada | Schedule I (Controlled Drugs and Substances Act) | Available as Hydromorph Contin and Dilaudid; controlled drug prescribing regulations applycitation needed |
| Australia | Schedule 8 (Controlled Drug — Poisons Standard) | TGA regulated; state and territory prescription requirementscitation needed |
| Germany | Anlage III (Betäubungsmittelgesetz / BtMG) | Most restrictive medicinal narcotic schedule; special prescription form (BtM-Rezept) requiredcitation needed |
| Japan | Narcotic (Narcotics and Psychotropics Control Act) | Approved for medical use in 2013[8] |
| European Union | Controlled narcotic (member-state schedules vary) | Regulated under 1971 UN Convention framework; individual member states set prescription requirements |
Frequently asked questions
What is Hydromorphone?
Hydromorphone is a semi-synthetic morphinan opioid and selective mu-opioid receptor agonist, approximately five times more potent than morphine. First synthesized in 1921 and clinically introduced in 1926 as Dilaudid, it remains widely prescribed for moderate-to-severe pain.
How long does Hydromorphone last?
Total duration by route of administration — Oral: 3 – 5 hours; Insufflated: 3 – 5 hours; Intravenous: 3 – 4 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Hydromorphone?
Psychedex publishes a dosage table for Hydromorphone on this page covering these routes of administration: intravenous, oral, insufflated. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Hydromorphone?
The highest-severity documented interactions for Hydromorphone: Benzodiazepines, Barbiturates (Lethal), GHB, Baclofen (Lethal), GHB, GBL (Lethal), Local anesthetics (Lethal), 5-HTP, Tryptophan (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Hydromorphone addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Hydromorphone: tolerance builds rapid; full reset takes 14 days; cross-tolerance develops with morphine, oxycodone, fentanyl, heroin, hydrocodone, methadone. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^Hanna M, Thipphawong J (2008) A randomized, double-blind comparison of OROS hydromorphone and controlled-release morphine for the control of chronic cancer pain — BMC Palliative Care doi:10.1186/1472-684x-7-17
- [2] ^abcVolpe DA, McMahon Tobin GA, Mellon RD, et al. (2011) Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs — Regulatory Toxicology and Pharmacology doi:10.1016/j.yrtph.2010.12.007
- [3]
- [4] ^abcMazer-Amirshahi M, Motov S, Nelson LS (2018) Hydromorphone use for acute pain: Misconceptions, controversies, and risks — Journal of Opioid Management doi:10.5055/jom.2018.0430
- [5]
- [6]
references
- [1] ^Hanna M, Thipphawong J (2008) A randomized, double-blind comparison of OROS hydromorphone and controlled-release morphine for the control of chronic cancer pain — BMC Palliative Care doi:10.1186/1472-684x-7-17
- [2] ^abcVolpe DA, McMahon Tobin GA, Mellon RD, et al. (2011) Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs — Regulatory Toxicology and Pharmacology doi:10.1016/j.yrtph.2010.12.007
- [3]
- [4] ^abcMazer-Amirshahi M, Motov S, Nelson LS (2018) Hydromorphone use for acute pain: Misconceptions, controversies, and risks — Journal of Opioid Management doi:10.5055/jom.2018.0430
- [5]
- [6]